DALLAS-FORT WORTH, TX., September 10, 2025 — Intrinsic Therapeutics, Inc., is a medical technology company committed to redefining the standard of care for lumbar discectomy patients with large annular defects by reducing reoperations for reherniations by 81%* with its Barricaid Annular Closure Device. Today, the company announced that Michael Briseño, MD of North Texas Orthopedics and Spine Center has achieved the distinction of Barricaid Gold Center of Excellence. This designation recognizes consistent clinical excellence and a sustained commitment to optimizing outcomes for high-risk discectomy patients.
“We are proud to recognize Dr. Briseño’s expertise in utilizing the Barricaid device. His thoughtful patient selection, meticulous technique, and rigorous follow-up display his commitment to providing positive long-term outcomes for his patients,” said Jake Tanner, VP Marketing, Intrinsic Therapeutics.
Barricaid is a bone-anchored annular closure device designed to close lumbar annular defects following limited discectomy. By addressing the defect at the time of surgery, Barricaid is proven to improve patient outcomes by preventing reherniation and reoperation. The Barricaid Center of Excellence program identifies and supports high-performing clinical teams that are advancing patient outcomes through the utilization of the Barricaid device.
“It’s an honor to be recognized as a Barricaid Gold Center of Excellence,” said Dr. Michael Briseño. “This distinction reflects the dedication of our entire care team – from preoperative assessment to intraoperative execution and postoperative follow-up. Our focus is simple: deliver consistent, evidence-informed care that helps the right patients at the right time.”
About Barricaid®
Barricaid is a proprietary technology designed to prevent reherniation and reoperation in patients with large annular defects following lumbar discectomy surgery. Barricaid has been implanted in over 12,000 patients and is supported by clinical studies across eight distinct patient populations, including two randomized controlled trials and six single-arm studies. A multicenter, Level I RCT demonstrating superior outcomes to discectomy alone was published in JAMA with five-year follow-up results.
*Some studies are outside FDA indications. Values at a minimum of 1-year post-op. Minimum study size: 20 Barricaid subjects.
Barricaid is a registered trademark of Intrinsic Therapeutics, Inc.
About North Texas Orthopedics & Spine Center
Since 1990, North Texas Orthopedics & Spine Center has been committed to providing each and every patient with the highest level of compassionate, specialized orthopedic, spine and sports medicine care. The orthopedic specialists are recognized leaders in the diagnosis and treatment of the musculoskeletal system, offering surgical and nonsurgical treatments for every bone, joint, muscle, tendon, and ligament injury and condition, including arthritis of the knee, ankle sprains, and hip fractures.
